Geron halted the Phase 3 IMpactMF trial of imetelstat in JAK inhibitor relapsed/refractory myelofibrosis following Data Monitoring Committee advice, although the company remains committed to its commercial RYTELO business.
Geron halted the Phase 3 IMpactMF trial of imetelstat in JAK inhibitor relapsed/refractory myelofibrosis following Data Monitoring Committee advice, although the company remains committed to its commercial RYTELO business.